Q-omics provides the consensus-scored KLHL14 profile across patient tissues and cancer cell-line models. KLHL14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KLHL14 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KLHL14 RNA expression shows 17,864 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where KLHL14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL14 survival associations across molecular data types. KLHL14 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL14 RNA expression–survival associations across cancer types. High KLHL14 expression shows unfavorable associations in UVM, OV and ACC, but favorable associations in HNSC, ESCA and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KLHL14 RNA expression.
This table summarizes KLHL14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL14 shows lower tumor expression in KIRC, KICH, KIRP, COAD, LUSC and HNSC. The KIRC box plot shows higher KLHL14 RNA expression in normal versus tumor tissue (log2 FC = −2.915, t-test p < 0.001).
This table shows molecular features associated with KLHL14 in patient tissues and cancer cell lines. In patient samples, KLHL14 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
